Bristol Myers Squibb (CELG-RI) Liabilities from Discontinued Operations (2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Liabilities from Discontinued Operations of 4931000000.0 for Q4 2013.
Bristol Myers Squibb (CELG-RI) Liabilities from Discontinued Operations (2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Liabilities from Discontinued Operations for 1 consecutive years, with 4931000000.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Liabilities from Discontinued Operations changed N/A year-over-year to 4931000000.0; the TTM figure through Dec 2013 stood at 4931000000.0 (changed N/A YoY), while the FY2013 annual figure was 4931000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations was little changed at 4931000000.0 in Q4 2013 per CELG-RI's latest filing.
- Across five years, Liabilities from Discontinued Operations topped out at 4931000000.0 in Q4 2013 and bottomed at 4931000000.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 4.93 Bn |
| Dec 31, 2013 | 4.93 Bn |